Medical Condition News

RSS

Research findings could help save lives from sick sinus syndrome

The pioneering research, using detailed computer models, could help save lives through preventative treatment of those most at risk from a form of heart rhythm disorder called sick sinus syndrome.

From The University of Manchester 7 Jul 2010

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

Caraco Pharmaceutical Laboratories, Ltd. has started shipping azelastine ophthalmic solution, 0.05%. This product was recently approved by the US Food and Drug Administration (FDA) for Sun Pharma's Abbreviated New Drug Application (ANDA).

7 Jul 2010

FDA approves Glassia for treating Alpha 1 deficiency

Kamada, today announced that the United States Food and Drug Administration has approved Glassia (Alpha 1 Proteinase inhibitor, also known as Alpha-1-Antitrypsin) for the treatment of Alpha 1 deficiency. GlassiaM is now the first and only liquid Alpha- 1-Proteinase Inhibitor worldwide available liquid, ready to use, Alpha- 1-Proteinase Inhibitor on the market.

7 Jul 2010

Shire receives FDA approval of Daytrana for ADHD in adolescents

Shire plc, the global specialty biopharmaceutical company, announced the US Food and Drug Administration (FDA) approval of Daytrana® (methylphenidate transdermal system) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adolescents aged 13 to 17 years. Daytrana, the first and only transdermal ADHD patch, is already an FDA-approved ADHD treatment for children 6 to 12 years. Daytrana is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, and social).

7 Jul 2010

Experts show the continuing global impact of Framingham Heart Study

Few medical investigations have had the impact of the Framingham Heart Study. This study, started in 1948, was designed as a cohort, observational study of cardiovascular disease, then recognized as a growing health threat but now has emerged as much more. The Framingham Heart study came to revolutionize thinking about cardiovascular disease, change the study of epidemiology, and even force the biostatistics community to develop multivariate analysis.

7 Jul 2010

US WorldMeds launches Revonto for malignant hyperthermia

US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH). The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear. Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

7 Jul 2010

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Sylentis, a biopharmaceutical subsidiary of Grupo Zeltia and a pioneer in the research and development of new drugs based on gene silencing (interference RNA, RNAi), has completed Phase Ia of its first clinical trial with SYL040012 in the form of ophthalmic drops to treat elevated intraocular pressure and glaucoma.

7 Jul 2010

Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter

Crux Biomedical®Inc. announced today that it has successfully enrolled the first patient in its Retrieve 2 pivotal U.S. IDE trial. The trial will evaluate the safety and efficacy of Crux's new Vena Cava Filter (VCF). The Crux VCF is a retrievable, implantable filter which is designed to trap blood clots that can lead to a potentially fatal pulmonary embolism (PE). It is the first VCF to be developed that is bidirectional and thus permits insertion or retrieval from either the femoral or jugular veins.

7 Jul 2010

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

PuraMed BioScience, announced today that a clinical study of LipiGesic M has been completed. The study design was a double blind, placebo controlled, multi-site study measuring the effectiveness of LipiGesic™ M for the treatment of acute migraine attacks. The next steps include completion of the manuscript, submission for publication in a peer-reviewed medical journal and actual publication. In an effort to maximize the potential for publication, an embargo has been placed on the disclosure of any of the results of this study.

7 Jul 2010

Pfizer's new chewable Lipitor for children receives European Commission approval

Pfizer Inc. announced it has received European Commission approval of a new chewable form of Lipitor (atorvastatin calcium) suitable for use in children aged 10 or older with high levels of LDL ("bad") cholesterol and high triglycerides due to the inherited disorder familial hypercholesterolemia and other primary causes, which can increase the risk of heart disease and premature death. This pediatric indication has also been approved for the currently available tablet form of Lipitor.

7 Jul 2010

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

In their latest research, scientists of the Max Delbr-ck Center for Molecular Medicine Berlin-Buch, Germany, have demonstrated how the brain's own stem cells and precursor cells control the growth of glioblastomas. Of all brain tumors, glioblastomas are among the most common and most aggressive.

7 Jul 2010

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

Angion Biomedica Corp., a biopharmaceutical company dedicated to the discovery and development of novel therapeutics that enhance quality of life, eradicate disease and save lives by modulating the body's protective, reparative and regenerative systems, announced today that its lead therapeutic BB3 was accepted into the Fast Track program of the U.S. Food and Drug Administration (FDA) and has also been designated an Orphan Drug product by FDA.

7 Jul 2010

POMC neurons suppress appetite, induce weight loss: Research

A protein found in cells throughout the body must be present in a specific set of neurons in the brain to prevent weight gain after chronic feeding on high-calorie meals, new findings from UT Southwestern Medical Center researchers suggest.

7 Jul 2010

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

Cornerstone Therapeutics Inc., a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has reacquired all development and commercial rights to its high-mobility group box protein 1 (HMGB1) related technology from MedImmune, LLC.

6 Jul 2010

CPRIT grants RBM $3 million Company Commercialization Award to expand OncologyMAP program

Rules-Based Medicine, Inc. (RBM) today announced the Cancer Prevention and Research Institute of Texas (CPRIT) has granted it a Company Commercialization Award to expand and enhance the OncologyMAP™ program for discovery and development of novel diagnostic and prognostic cancer tests. The award of approximately $3 million will fund research and development to more than double the number of cancer-associated biomarker assays in RBM's new OncologyMAP™ product.

6 Jul 2010

Amorfix partners with reMYND to offer A4 amyloid testing services

Amorfix Life Sciences Ltd. and reMYND NV today announced the signing of a partnership agreement to offer the Amorfix A4 amyloid testing service to reMYND's contract research clients. reMYND's contract research business offers an extensive portfolio of preclinical in-vivo efficacy, pharmacokinetic and safety testing of experimental Alzheimer therapies using proprietary mouse models of Alzheimer's disease (AD).

6 Jul 2010

EMA completes validation process for Dyax's ecallantide MAA

Dyax Corp. announced today that the European Medicines Agency (EMA) has completed its validation process for the Marketing Authorization Application (MAA) for potential approval to market DX-88 (ecallantide) in the European Union (EU).

6 Jul 2010

Training for first responders on antidote for acute cyanide poisoning from fire smoke

Since January 1, 2010 the CPTC has tracked 1,100 civilians treated for smoke inhalation, 413 smoke inhalation deaths, and 125 firefighters who were transported for smoke inhalation treatment. Contrary to popular belief, whether a civilian or a firefighter, smoke inhalation isn't a minor injury - it's deadly.

6 Jul 2010

Elsevier, SIOG launch Journal of Geriatric Oncology

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, and the International Society of Geriatric Oncology (SIOG) announced today the launch of the Journal of Geriatric Oncology. The journal is focused on advancing research in the pathogenesis, biology, treatment, and survivorship issues of older adults with cancer. It covers all aspects of geriatric oncology, from basic scientific research through to clinical research, as well as research that is relevant to education and policy development.

6 Jul 2010

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Adeona Pharmaceuticals, Inc., announced today that on July 6, 2010, it completed an equity financing of $1 million with a single institutional investor, Seaside 88, L.P. The financing involved the sale of 1,212,121 registered shares of common stock and no warrants. Enclave Capital served as placement agent and will receive a 7% cash commission and 5-year warrants to acquire 60,606 shares of Adeona at $1.32 per share. The use of proceeds is intended for general corporate purposes.

6 Jul 2010

Medical Condition News

Research findings could help save lives from sick sinus syndrome

Caraco Pharmaceutical Laboratories commences shipping azelastine ophthalmic solution

FDA approves Glassia for treating Alpha 1 deficiency

Shire receives FDA approval of Daytrana for ADHD in adolescents

Experts show the continuing global impact of Framingham Heart Study

US WorldMeds launches Revonto for malignant hyperthermia

Phase Ia clinical trial of SYL040012 for treating elevated intraocular pressure, glaucoma completed

Crux Biomedical commences enrollment in Retrieve 2 pivotal U.S. IDE trial of new Vena Cava Filter

PuraMed BioScience completes clinical study of LipiGesic M for treating acute migraine

Pfizer's new chewable Lipitor for children receives European Commission approval

Scientists demonstrate how neural stem cells, precursor cells control growth of glioblastomas

FDA grants Angion Biomedica's BB3 therapeutic Fast Track and Orphan Drug product designations

POMC neurons suppress appetite, induce weight loss: Research

Cornerstone reacquires all development, commercial rights to HMGB1 related technology from MedImmune

CPRIT grants RBM $3 million Company Commercialization Award to expand OncologyMAP program

Amorfix partners with reMYND to offer A4 amyloid testing services

EMA completes validation process for Dyax's ecallantide MAA

Training for first responders on antidote for acute cyanide poisoning from fire smoke

Elsevier, SIOG launch Journal of Geriatric Oncology

Adeona completes $1 million equity financing and provides update on Zinthionein ZC clinical study

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News